Compare Dyne Therapeutics Inc. Common Stock (DYN) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs NEOS S&P 500 High Income ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while NEOS S&P 500 High Income ETF trades at $53.55 (market cap $12.59B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 4.4× Dyne Therapeutics Inc. Common Stock's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and NEOS S&P 500 High Income ETF for 59 Days on average.
| DYN | SPYI | |
|---|---|---|
Market Cap | $2.86B | $12.59B |
Volume | 3,341,579 | 1,834,804 |
Sector | Health | Income / Options Overlay |
52-Week High | $26.78 | $54.42 |
52-Week Low | $14.60 | $47.98 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SPYI trades at $54.11 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. Recent news highlights SPYI's role in income-focused portfolios while raising concerns about principal erosion from covered call strategies. The ETF's dividend payments remain consistent with recent distributions around $0.53-0.54 per share.
The outlook for SPYI balances high income generation against capital preservation risks. While the covered call strategy provides attractive yields, investors face potential principal erosion during market rallies. Recent analyst coverage suggests a cautious approach given the trade-offs between income stability and growth limitations inherent in the fund's strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
